IMMUNOTHERAPY BRIDGE
December 1st-2nd, 2021

SCIENTIFIC PROGRAM

Wednesday, Dec 1st, 2021

10:30 am

Introduction and objectives
Paolo A. Ascierto

SITC SESSION
LESSONS LEARNED FROM CELL THERAPIES
Chairpersons: Patrick Hwu, Bernard A. Fox

10:40 am

CAR-T
Chrystal Paulos

10:55 am

Targeting solid malignancies with ‘public’ neoantigen-specific T cell receptors

Christopher Klebanoff

11:10 am

Harnessing the power of a natural killer: bringing NK cells to immuno-oncology
Tamara Laskowski

11:25 am

Understanding resistance to develop better CAR T immunotherapies
Marco Ruella

11:40 am

Best of SITC 2021 for clinical development and trials
Paolo A. Ascierto

11:55 am

Discussion

12:25 pm

LECTURE – Immunotherapy in Renal Cell Carcinoma: update and new perspectives
Chairperson: Paolo A. Ascierto
Speaker: Giuseppe Procopio

12:55 pm

Lunch**

01:45 pm

SYMPOSIUM – Combinations therapy across cancers
Chairperson: Paolo A. Ascierto
NSCLC, Cesare Gridelli – RCC, Camillo Porta – Melanoma, Paolo A. Ascierto

SESSION 2
TRENDS IN IMMUNOTHERAPY
Chairpersons: John B. Haanen, Sandro Pignata

02:35 pm

Integrating Head and Neck Cancer Immunotherapy into Locally Advanced Treatment
Robert Ferris

02:50 pm

Pancreatic Cancer
Elizabeth Jaffee

03:05 pm

Kidney Cancer
Sergio Bracarda

03:20 pm

GI cancer
Antonio Avallone

03:35 pm

Implications of the Tumor Microenvironment for Breast Cancer Immunotherapy
Leisha A. Emens

03:50 pm

Ovarian Cancer
Sandro Pignata

04:05 pm

Coffee Break**

04:20 pm

PDI-blockade for Hodgkin Lymphoma: results, challenges and opportunities
Antonio Pinto

04:35 pm

Lecture: Merkel Cell Carcinoma
Paolo A. Ascierto

04:50 pm

Discussion

GREAT DEBATE SESSION
Chairpersons: Paolo A. Ascierto, Bernard A. Fox, Patrick Hwu, Igor Puzanov

05:20 pm

Have B-cells a therapeutic role in the response to cancer immunotherapy? Yes or No
Wolf Fridman, Tullia Bruno

05:50 pm

Discussion

06:00 pm

Intralesional therapy: oncolytic virus VS other specific immune modulators
Igor Puzanov, Omid Hamid

06:30 pm

Discussion

06:40 pm

Do early surrogates correlate with long-term overall survival? Yes or No
Michael A. Postow, Jeffrey Sosman

07:10 pm

Discussion

IMMUNOTHERAPY BRIDGE
December 1st-2nd, 2021

SCIENTIFIC PROGRAM

Thursday, Dec 2nd, 2021

SESSION 3
DRIVERS OF IMMUNE RESPONSES
Chairpersons: Alfredo Budillon, Bernard A. Fox

09:00 am

Biotechnology tricks to harness CD137 (4-1BB) costimulation for cancer
immunotherapy
Ignacio Melero Bermejo

09:15 am

Super CD8-T cells, a new tool in immunotherapy; T cell reprograming
Samir Khleif

09:30 am

Immunotherapy for non-immunogenic tumors
Nina Bhardvaj

09:45 am

Role of dendritic cells in immune response
Joshua Brody

10:00 am

Pre-existing immune contexture for immunotherapy response
Jerome Galon

10:30 am

Discussion

10:45 am

Coffee Break**

10:55 am

Predicting and mapping tumor regression following neoadjuvant immunotherapy
Janis M. Taube

11:10 am

The virtual molecular tumor board as a tool for the delivery of precision oncology
Carlo Bifulco

11:25 am

A new perspective on therapy-modulated tumor antigenicity
Sandra Demaria

11:40 am

Cancer vaccine concepts for solving infectious diseases
Luigi Buonaguro

11:55 am

PDL1 and IDO targeting vaccination for treatment of metastatic cancer
Inge Marie Svane

12:10 pm

Discussion

12:25 pm

SYMPOSIUM – Non-Melanoma Skin Cancer
Chairpersons: Paolo A. Ascierto
Paolo A. Ascierto, Dirk Schadendorf

01:15 pm

Lunch**

GREAT DEBATE SESSION
Chairpersons: Paolo A. Ascierto, Bernard Fox, Igor Puzanov

02:00 pm

Can vaccine transform cold into hot tumors? Yes or No
Olivera Finn, Lisa H. Butterfield

02:30 pm

Discussion

02:40 pm

Data science approaches to gain insights in to IO development:
broad vs deep analytics
Theresa LaValle, Andrew Futreal

03:10 pm

Discussion

03:20 pm

Coffee Break**

SESSION
NEO ADJUVANT IMMUNOTHERAPY ACROSS CANCERS
Chairpersons: Paolo A. Ascierto, Elizabeth Burton

03:30 pm

Overview and GU cancer
Padmanee Sharma

03:45 pm

Breast Cancer
Elizabeth Mittendorf

04:00 pm

Colon cancer
Myriam Chalabi

04:15 pm

NSCLC
Tina Cascone

04:30 pm

Melanoma
Rodabe Amaria

04:45 pm

NMSC as Model for Neoadjuvant Immunotherapy
Neil Gross

05:00 pm

Refining pathological response assessment in neoadjuvant therapy for melanoma
Richard Scolyer

05:15 pm

Discussion

05:45 pm

Conclusions
Paolo A. Ascierto, Bernard Fox, Igor Puzanov